UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma

Pigment cell and melanoma research, 2019-07, Vol.32 (4), p.603-606

2019

Link zum Volltext

Verfügbarkeit prüfen

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS‐mutant and wild‐type melanoma

Pigment cell and melanoma research, 2018-01, Vol.31 (1), p.110-114

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1102-1109.e1

2014

Link zum Volltext

Verfügbarkeit prüfen

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

Proceedings of the National Academy of Sciences - PNAS, 2013-03, Vol.110 (10), p.4015-4020

2013

Link zum Volltext

Verfügbarkeit prüfen

DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics

Nanoscale, 2014-01, Vol.6 (13), p.7436-7442

2014

Link zum Volltext

Verfügbarkeit prüfen

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600 E/K mutant advanced melanoma

Pigment cell and melanoma research, 2019-07, Vol.32 (4), p.603-606

2019

Link zum Volltext

Verfügbarkeit prüfen

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas

Oncotarget, 2018-10, Vol.9 (79), p.34990-34995

2018

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma

PloS one, 2014-09, Vol.9 (9), p.e107255-e107255

2014

Link zum Volltext

Verfügbarkeit prüfen

Searching for the Chokehold of NRAS Mutant Melanoma

Journal of investigative dermatology, 2016-07, Vol.136 (7), p.1330-1336

2016

Link zum Volltext

Verfügbarkeit prüfen

Modeling Inducible Human Tissue Neoplasia Identifies an Extracellular Matrix Interaction Network Involved in Cancer Progression

Cancer cell, 2009-06, Vol.15 (6), p.477-488

2009

Link zum Volltext

Verfügbarkeit prüfen

Stable nonviral genetic correction of inherited human skin disease

Nature medicine, 2002-10, Vol.8 (10), p.1166-1170

2002

Link zum Volltext

Verfügbarkeit prüfen

Type VII Collagen Is Required for Ras-Driven Human Epidermal Tumorigenesis

Science (American Association for the Advancement of Science), 2005-03, Vol.307 (5716), p.1773-1776

2005

Link zum Volltext

Verfügbarkeit prüfen

Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

PloS one, 2015-04, Vol.10 (4), p.e0126988-e0126988

2015

Link zum Volltext

Verfügbarkeit prüfen

Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue

The Journal of clinical investigation, 2003-01, Vol.111 (2), p.251-255

2003

Link zum Volltext

Verfügbarkeit prüfen

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies

Oncotarget, 2014-09, Vol.5 (17), p.7936-7944

2014

Link zum Volltext

Verfügbarkeit prüfen

A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation

Cancer research (Chicago, Ill.), 2007-05, Vol.67 (9), p.4264-4270

2007

Link zum Volltext

Verfügbarkeit prüfen

Poor melanoma outcomes and survival in Asian American and Pacific Islander patients

Journal of the American Academy of Dermatology, 2021-06, Vol.84 (6), p.1725-1727

2021

Link zum Volltext

Verfügbarkeit prüfen

Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma

Journal of investigative dermatology, 2015-10, Vol.135 (10), p.2475-2483

2015

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

JAMA dermatology (Chicago, Ill.), 2015-11, Vol.151 (11), p.1206

2015

Link zum Volltext

Verfügbarkeit prüfen

Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema

International journal of dermatology, 2004-01, Vol.43 (1), p.51-54

2004

Link zum Volltext

Verfügbarkeit prüfen

NRAS mutant melanoma--undrugable?

Oncotarget, 2013-04, Vol.4 (4), p.494-495

2013

Link zum Volltext

Verfügbarkeit prüfen

Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment

Oncotarget, 2023-05, Vol.14, p.543-560

2023

Link zum Volltext

Verfügbarkeit prüfen

Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox

Clinical, cosmetic and investigational dermatology, 2015-01, Vol.8 (default), p.423-429

2015

Link zum Volltext

Verfügbarkeit prüfen

Erythema induratum Bazin-Nodulärvasculitis

Journal der Deutschen Dermatologischen Gesellschaft, 2004-03, Vol.2 (3), p.206-215

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(54)
Berichte
(1)

Sprache

Englisch
(54)
Japanisch
(10)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS‐mutant and wild‐type melanoma

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600 E/K mutant advanced melanoma

The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma

Searching for the Chokehold of NRAS Mutant Melanoma

Modeling Inducible Human Tissue Neoplasia Identifies an Extracellular Matrix Interaction Network Involved in Cancer Progression

Stable nonviral genetic correction of inherited human skin disease

Type VII Collagen Is Required for Ras-Driven Human Epidermal Tumorigenesis

Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies

A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation

Poor melanoma outcomes and survival in Asian American and Pacific Islander patients

Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema

NRAS mutant melanoma--undrugable?

Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment

Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox

Erythema induratum Bazin-Nodulärvasculitis

Suchergebnisse filtern